Inactive Instrument

Aoxing Pharmaceutical Company Inc Stock Nyse

Equities

US03740A1060

Pharmaceuticals

Sales 2015 25.48M Sales 2016 32.33M Capitalization 49.54M
Net income 2015 5M Net income 2016 2M EV / Sales 2015 5.77 x
Net Debt 2015 24.8M Net Debt 2016 18.56M EV / Sales 2016 2.11 x
P/E ratio 2015
20.1 x
P/E ratio 2016
23.2 x
Employees -
Yield 2015 *
-
Yield 2016
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
Aoxing Pharmaceutical Company, Inc. Executive Changes CI
Aoxing Pharmaceutical Company, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2017 CI
Aoxing Pharmaceutical Company, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2016 CI
Aoxing Pharmaceutical Company, Inc. Announces Unaudited Consolidated Earnings Results for First Quarter Ended Sept. 30, 2016 CI
Aoxing Pharmaceutical Company, Inc. Reports Earnings Results for the Year Ended June 30, 2016 CI
Aoxing Pharmaceutical Company, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2016 CI
Aoxing Pharmaceutical Company, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2015; Provides Earnings Guidance for the Fiscal Year 2016 CI
Aoxing Pharmaceutical Company, Inc. Announces Executive Changes CI
Aoxing Pharmaceutical Company, Inc. to Supply Zhongtongan to the Insurance System for the City of Shanghai CI
Aoxing Pharmaceutical Company, Inc. Announces Opening of its New Narcotic and Psychotropic Drug Research Center CI
Aoxing Pharmaceutical Company, Inc. Announces Management Changes CI
Aoxing Pharmaceutical Company, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2015 CI
Aoxing Pharmaceutical Company, Inc. Auditor Raises 'Going Concern' Doubt CI
Aoxing Pharmaceutical Company, Inc. Announces Consolidated Earnings Results for the Year Ended June 30, 2015; Provides Earnings Guidance for the Fiscal Year 2016 CI
Aoxing Pharmaceutical Company, Inc. Announces Management Changes CI
More news
Managers TitleAgeSince
Chief Executive Officer - 23-08-10
Chief Tech/Sci/R&D Officer 69 10-12-31
Sales & Marketing - -
Members of the board TitleAgeSince
Chief Executive Officer - 23-08-10
More insiders
Aoxing Pharmaceutical Company, Inc. is a specialty pharmaceutical company specializing in research, development, manufacturing and distribution of a range of narcotic, pain-management and addiction treatment pharmaceutical products. The Company holds approximately 140 drug production certificates covering narcotic pain-management, prescription medicines, over-the-counter (OTC) and active pharmaceutical ingredient (API) products. Its products include prescription drugs, such as Tilidine hydrochloride, Zhongtong'an and Humifuse Euphorbia Herb Tablet, and OTC drugs, such as Shanmei Capsule, Shaoshang Tincture, Yiqi Qiangshen Granule, Xiaopiling Granule, Xiongjushangqing Tablet, Juyuansuanbijia Oral Solutions, Longdanxiegan Tablet, Fenka Tablet, Shujinhuoxue Tablet, Fuketiaojing Tablet, Qingnao Jiangya Tablet, Yuanhu Pain Management Tablet, Bushenqiangshen Tablet, Baiziyangxin Pill, Qingguo Pill, Liuweidihuang Pill, Zhibaidihuang Pill, Xiaoyao Pill and Tianwangbuxin Pill.
More about the company